Response rates and adverse effects of continuous once-daily sunitinib in patients with advanced renal cell carcinoma: a single-center study in Turkey.


Yildiz İ. , Sen F., Basaran M., Ekenel M., Agaoglu F. , Darendeliler E., ...Daha Fazla

Japanese journal of clinical oncology, cilt.41, ss.1380-7, 2011 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 41 Konu: 12
  • Basım Tarihi: 2011
  • Doi Numarası: 10.1093/jjco/hyr151
  • Dergi Adı: Japanese journal of clinical oncology
  • Sayfa Sayıları: ss.1380-7

Özet

Objective: Therapy targeted against the vascular endothelial growth factor pathway is a standard of care for patients with metastatic renal cell carcinoma. This study assessed the response rates and toxicity profiles of sunitinib on a continuous once-daily dosing regimen in Turkish patients with metastatic renal cell carcinoma.